MB
IRON icon

MPM BioImpact’s Disc Medicine IRON Stock Holding History

MPM BioImpact’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-346,401
Closed -$22M – 49
2024
Q4 		$22M Buy
346,401
+34,640
+11% +$2M 3.12% 7
2024
Q3 		$15.3M Buy
311,761
+6,103
+2% +$287K 2.3% 16
2024
Q2 		$13.8M Buy
305,658
+194,879
+176% +$6.62M 2.14% 13
2024
Q1 		$6.9M Buy
110,779
+60,779
+122% +$3.94M 1.11% 35
2023
Q4 		$2.89M Buy
+50,000
New +$2.56M 0.68% 29

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MPM BioImpact's IRON Position: Q1 2025 in Review

MPM BioImpact sold out of Disc Medicine (IRON) in Q1 2025, closing a stake of 346,401 shares — an estimated $22M sold.

MPM BioImpact first reported a position in IRON in Q4 2023 and held it in 5 quarters. The position peaked at $22M in Q4 2024. 157 funds tracked by Wall St. Rank hold IRON as of Q1 2025.

  • MPM BioImpact reported no remaining Disc Medicine position as of Q1 2025 after selling out during the quarter.
  • MPM BioImpact sold 346,401 Disc Medicine shares in Q1 2025, an estimated $22M.
  • MPM BioImpact first reported a position in Disc Medicine in Q4 2023 and held it in 5 quarters.
  • MPM BioImpact's Disc Medicine position peaked at $22M in Q4 2024.
  • 157 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2025.

Based on MPM BioImpact's 13F filing for Q1 2025, filed 15 May 2025.